However, blood-derived human neutrophils of some tumor patients (squamous cell carcinoma [44]; B cell chronic lymphocytic leukemia [45]) expressed less TRAIL than healthy donors and IFNα-therapy in vivo enhanced TRAIL expression on neutrophils of chronic myeloid leukemia (CML) patients [18]. This evidence concerns the gene TNFSF10 and chronic myelogenous leukemia, BCR-ABL1 positive.